Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

 An expert describes his perspective on sequencing, APRIL inhibition, proteinuria endpoints, and long-term kidney preservation in IgA nephropathy.



APRIL Inhibition, Dual Blockade, and Proteinuria Endpoints in IgAN, With Edward Lerma, MD

On IgAN Awareness Day, clinicians highlight earlier diagnosis, dynamic risk stratification, and emerging targeted therapies reshaping care.

IgAN Enters “Mechanism-First Era” Reframing Diagnosis, Treatment, and Remission

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

The HCPFive: Top News for Healthcare Providers from the Week of 04/19

Ravulizumab reduced proteinuria by week 10 and met the primary endpoint in the phase 3 I CAN trial in IgA nephropathy.


Ravulizumab Reduces Proteinuria as Early as Week 10 in Phase 3 I CAN Trial for IgAN

Catch up on nephrology headlines you missed from Q1 2026.

Q1 2026 Recap: Nephrology News and Updates

HCPLive’s editorial team has compiled 5 of the most informative discussions, along with key data from the WCN. 

WCN 2026 Recap: 5 Key Updates in Kidney Disease to Know 

2-year results from phase 3 APPLAUSE-IgAN demonstrate slower eGFR decline, reduced composite kidney failure, and proteinuria in IgAN patients treated with iptacopan. 


APPLAUSE-IgAN: Iptacopan (Fabhalta) Exhibits 49.3% Slower eGFR Decline in IgAN Patients Than Placebo

Norouzi discussed the remaining challenges that come with having evolving treatment options and a robust patient population in IgAN.

New Therapeutic Options Raise More Questions for IgA Nephropathy Treatment, With Sayna Norouzi, MD

Catch up on the guideline updates, trial news, and featured content from March 2026. 


5 Nephrology Headlines You Missed in March 2026

Data presented at the World Congress of Nephrology highlight faster and higher rates of microscopic hematuria negativity with sibeprenlimab treatment.

New VISIONARY Analyses Reinforce Benefits of APRIL Inhibition With Sibeprenlimab in IgAN

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.